Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
Kurreck A, Geissler M, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Stintzing S, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Modest DP.
Kurreck A, et al. Among authors: ettrich t.
J Cancer Res Clin Oncol. 2020 Oct;146(10):2681-2691. doi: 10.1007/s00432-020-03257-z. Epub 2020 May 24.
J Cancer Res Clin Oncol. 2020.
PMID: 32449003
Free PMC article.
Clinical Trial.